San Francisco--A commonly prescribed antibiotic and alpha-blocker appear to be ineffective in the treatment of men with moderate to severe chronic prostatitis/chronic pelvic pain syndrome of long duration. Results of a multicenter study found that both ciprofloxacin and tamsulosin-used primarily in the treatment of urinary tract infections and BPH, respectively-offered no significant benefit in the treatment of chronic prostatitis in patients who were heavily pretreated and had long-standing symptoms.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.